We used a CAR directed to the antigen PTPRZ1, previously identified by our group as a relevant tumor-associated cell surface protein in glioblastoma (GBM)42,43 and used as part of the IMA950 multi-peptide vaccine in phase I/II clinical trials.44 This evidence concerns the gene PTPRZ1 and neoplasm.